Challenger Limited

State Street Corporation has ceased to be a substantial holder in Challenger Limited as of August 21, 2025. This change may affect the company's shareholder structure and market influence. The latest analyst rating for Challenger (AU:CGF) is a Buy, with a price target of A$9.20. Challenger's year-to-date price performance is 48.33%, with an average trading volume of 2,658,586 and a current market cap of A$5.97 billion.

Tip Ranks

State Street Corporation Ceases Substantial Holding in Challenger Limited

Challenger Limited reported a significant variation in its normalised net profit after tax for 2025, diverging from forecasts. The company cautioned that future earnings projections are subject to change due to various uncontrollable factors and highlighted potential risks. Market and industry trends were discussed in the outlook, reflecting the dynamic market conditions. The 2025 Annual Report is available on their website for investors and stakeholders.

Reuters

Challenger Limited Reports Significant Variation in Normalised Net Profit After Tax for 2025; Earnings Diverge from Forecasts

Challenger Limited (AU:CGF) reported strong FY25 results, with a 9% increase in normalized net profit after tax to $456 million, meeting earnings guidance. The company achieved record sales in retail lifetime and Japanese annuities, driven by strategic initiatives and digital transformation. Challenger declared a fully franked dividend of 29.5 cents per share, an 11% increase from last year. Despite positive performance, the latest analyst rating on CGF stock is a Sell with a price target of A$6.60. The company focuses on retirement income products and has a market cap of A$5.8B.

Challenger Limited Reports Strong FY25 Results and Strategic Growth

LYSDY

Challenger Limited has increased its stake in Lynas Rare Earths Ltd, raising its voting power from 5.08% to 6.12%. This change reflects a rise in shares held and may influence shareholder dynamics and strategic decisions at Lynas. The latest analyst rating for Lynas (AU:LYC) is a Buy, with a price target of A$7.15. Lynas Rare Earths has a current market cap of A$8.68B and an average trading volume of 4,998,774 shares.

Lynas Corporation

Challenger Limited Increases Stake in Lynas Rare Earths

Challenger Limited has appointed David Whittle as a director, effective June 17, 2025. Whittle currently holds no relevant interests in securities, indicating a focus on governance. This appointment may influence the company's strategic direction and governance structure. The latest analyst rating for Challenger (AU:CGF) stock is a Hold with a price target of A$7.00. Challenger operates in the financial services sector, specializing in retirement income products and services, with a current market cap of A$5.4B.

Challenger Limited Appoints New Director, David Whittle

Qube Holdings Limited (ASX:QUB) has 52% institutional ownership, indicating significant influence over its share price. A total of 16 investors hold a majority stake, with Challenger Limited being the largest shareholder at 7.2%. Insider ownership is also notable, with insiders holding AU$170m worth of shares. The general public owns 46% of the company, which can impact policies collectively. While institutional ownership suggests credibility, potential risks exist if large investors sell simultaneously. Investors should consider various factors, including analyst forecasts, before making investment decisions.

Simplywall

With 52% institutional ownership, Qube Holdings Limited (ASX:QUB) is a favorite amongst the big guns

Challenger Limited and its associated entities have ceased to be substantial holders in Integral Diagnostics Ltd. This change may affect the shareholder composition and market position of Integral Diagnostics, as substantial holders typically wield significant voting power. Integral Diagnostics has experienced a year-to-date price performance decline of 16.90% and currently has a market cap of A$890.1M.

Challenger Limited Ceases to be Substantial Holder in Integral Diagnostics

Challenger Limited has reduced its stake in IRESS Limited from 8.23% to 7.20%, impacting its voting power and potential influence over the company. This change may affect stakeholders monitoring IRESS's strategic decisions. IRESS Limited's year-to-date price performance is down 25.18%, with an average trading volume of 154 and a current market cap of €773.6M.

IRESS Limited

Challenger Limited Adjusts Stake in IRESS Limited

Challenger Limited (ASX:CGF) has a high P/E ratio of 28.5x, compared to the Australian average of below 17x. Despite recent earnings decline, analysts forecast a 48% annual EPS growth over the next three years, outpacing the market's 15%. This optimistic outlook justifies the elevated P/E, as investors anticipate recovery. However, caution is advised due to potential risks, with three warning signs identified for the company.

Challenger Limited's (ASX:CGF) Price In Tune With Earnings

Challenger Limited (AU:CGF) announced the issue price for its interim 2025 Dividend Reinvestment Plan (DRP) at $5.5314 per share, with a participation rate of 2% of issued capital. The plan was neutralized by purchasing 352,203 ordinary shares worth approximately $2 million. Challenger Limited is an investment management firm focused on retirement financial security, with a current market cap of $2.34B and a year-to-date price performance of -15.54%.

Challenger Limited Announces Interim 2025 DRP Details

Challenger Limited has updated its substantial holding in IRESS Limited, reducing its voting power from 10.37% to 9.25%. This change may affect shareholder dynamics within IRESS. The company, which provides financial technology solutions, has seen a year-to-date price performance of -14.98% and has a current market cap of €869M. For more detailed stock analysis, visit TipRanks’ Stock Analysis page.

Challenger Limited Updates Substantial Holding in IRESS Limited

Challenger Limited (AU:CGF) has released an investor presentation for the Jefferies Asia Forum, emphasizing its commitment to financial security for retirement and leadership in the annuities market. The firm operates a fiduciary Funds Management division and an APRA-regulated Life division, with Challenger Life Company being Australia's largest annuities provider. Current market cap is $2.34B, with a year-to-date price performance of -15.54% and a consensus rating of 'Buy'.

Challenger Limited Releases Investor Presentation for Jefferies Asia Forum

Challenger Limited has announced its status as a substantial holder in Integral Diagnostics Limited, acquiring 5.40% voting power. This strategic acquisition enhances Challenger's investment portfolio and may influence its market positioning in the healthcare diagnostics sector. Challenger Limited is a financial services company focused on retirement and investment solutions, with a current market cap of $2.55B and a year-to-date price performance of 1.66%.

Integral Ad Science

Challenger Limited Becomes Substantial Holder in Integral Diagnostics

Challenger Limited reported a rise in fiscal H1 earnings, with earnings per diluted share increasing to AU$0.103 from AU$0.081. Revenue, excluding insurance contracts, reached AU$1.23 billion, up from AU$1.2 billion. Insurance revenue also grew to AU$334.9 million from AU$303.8 million. The company anticipates a net profit after tax between AU$440 million and AU$480 million for fiscal 2025. An interim dividend of AU$0.145 per share was declared, payable on March 18 to shareholders on record as of Feb. 26.